

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Jun 2026

The adjuvant effect of dexamethasone to ondansetron or metoclopramide in prevention of nausea and vomiting after spinal anesthesia for elective caesarian section

Protocol summary

Study aim

The adjuvant effect of dexamethasone to ondansetron or metoclopramide in the prevention of nausea and vomiting after spinal anesthesia for elective cesarean section.

Design

This study will be done in the operating room. All of the drugs solution of this study will be prepared by only one person who is aware of the study's grouping, in 5 ml syringes in the same shape. Anesthesiologist, patients, and all medical staff that will collaborate in the study will not aware of the drug allocated to each patient.

Settings and conduct

In the present double-blind clinical trial, which will be carried out in a parallel way, a total of 150 patients who will be undergoing elective cesarean section under spinal anesthesia will be enrolled. Eligible patients will be randomly allocated into two equal A and B groups by block randomization.

Participants/Inclusion and exclusion criteria

Inclusion criteria: adult female with ASA class I or II, age between the 18 and 35, who are planned to undergo elective cesarean section under spinal anesthesia. Exclusion criteria: ASA class of III or IV, Allergies to local anesthetics and study medication, Hypertension caused by pregnancy, Patients whom emergency cesarean section is required.

Intervention groups

Intervention group 1 or DO group: dexamethasone 8 mg (manufactured by Tehran-Shimi Company) IV plus ondansetron 4 mg (manufactured by Caspin Company) is administered intravenously 10 minutes before anesthesia; Intervention group 2 or group DM: dexamethasone (manufactured by Tehran-Shimi Company) 8 mg IV, metoclopramide (manufactured by Caspin Company) 10 mg IV administered intravenously 10 minutes before anesthesia.

Main outcome variables

Nausea and Vomiting

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20221127056627N1**

Registration date: **2022-12-04, 1401/09/13**

Registration timing: **registered_while_recruiting**

Last update: **2022-12-04, 1401/09/13**

Update count: **0**

Registration date

2022-12-04, 1401/09/13

Registrant information

Name

Zeinabsadat Fattahi Saravi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3647 4270

Email address

zefattahi@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-11-21, 1401/08/30

Expected recruitment end date

2023-05-20, 1402/02/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
The adjuvant effect of dexamethasone to ondansetron or metoclopramide in prevention of nausea and vomiting after spinal anesthesia for elective caesarian section

Public title
Survey the effect of adding dexamethasone to ondansetron or metoclopramide to increase the effect of these drugs in prevention of nausea and vomiting after caesarian section under spinal anesthesia

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Adult women with ASA grade I or II (American Society of Anesthesiology classification) Women between 18 and 35 years old Women having elective caesarean section under spinal anesthesia
Exclusion criteria:
ASA class of III or IV pregnancy induced Hypertension Patients who have received steroid medication positive history of prolonged QT interval patients who refused to do spinal anesthesia for her

Age
From **18 years** old to **35 years** old

Gender
Female

Phase
4

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

Sample size
Target sample size: **150**

Randomization (investigator's opinion)
Randomized

Randomization description
Patients will be randomly allocated into two groups by block randomization. In this technique, a permutation block of size 6 will be made for patients of two groups A & B. In each block, equal numbers for two groups will be considered in alternative positions. Then 25 blocks of size 6 will be selected randomly and patients will be allocated randomly and equally into three groups according to these permutation block. block sequence will be prepared by www.sealedenvelope.com.

Blinding (investigator's opinion)
Double blinded

Blinding description
Antiemetic drugs are provided in the form of syringes containing 5 ml of normal saline solution by the first person, these drugs, which have the same color and size and in similar colors, are injected by the second person who is completely unaware of the contents of the syringes. The anesthesiologist, patients, and other

personnel involved in the work are blinded to the drugs injected in this study. This study is double-blind

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Shiraz Medical School
Street address
3rd Floor, 3rd building of the Shiraz Medical School, Zand Blvd.
City
Shiraz
Province
Fars
Postal code
197871345

Approval date
2022-07-16, 1401/04/25

Ethics committee reference number
IR.SUMS.MED.REC.1401.216

Health conditions studied

1

Description of health condition studied
cesarean section

ICD-10 code
O82

ICD-10 code description
Encounter for cesarean delivery without indication

Primary outcomes

1

Description
Nausea

Timepoint
3 minutes and 15 minutes before the operation and 4 hours after the operation

Method of measurement
Score points based on Bellavia criteria

2

Description
Vomiting

Timepoint
3 minutes and 15 minutes before the operation and 4

hours after the operation.

Method of measurement

Score points based on Bellavia criteria

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1 or DO group: dexamethasone 8 mg (manufactured by Tehran-Shimi Company) IV plus ondansetron 4 mg (manufactured by Caspin Company) is administered intravenously ten minutes before anesthesia.

Category

Treatment - Drugs

2

Description

Intervention group 2 or group DM: dexamethasone 8 mg((Manufactured by Tehran-Shimi Company) intravenously., and metoclopramide 10 mg (Made by Caspian Company) administered intravenously 10 minutes before anesthesia.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Ghadir Mother and Child Hospital

Full name of responsible person

Mojtaba Soukhakian

Street address

Ghadir Mother and Child Hospital-the beginning of Golshan town -above the Quran gate -Shiraz

City

Shiraz

Province

Fars

Postal code

۷۱۴۴۹۹۵۳۷۷

Phone

+98 71 3227 9701

Email

Motherhosp@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr Mahtab Memarpour

Street address

7th floor, central building of Shiraz University of Medical Sciences, Vice Chancellor of research, Zand street

City

Shiraz

Province

Fars

Postal code

7134844119

Phone

+98 71 3235 7282

Fax

+98 71 3212 2430

Email

memarpour@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Mojtaba Sookhakistan

Position

Anesthesiology resident/physician

Latest degree

Medical doctor

Other areas of specialty/work

Anesthesiology

Street address

Anesthesiology Department, Faghihi Hospital, Zand Street

City

Shiraz

Province

Fars

Postal code

7134844119

Phone

0987136474270

Email

dr.sookhian.m@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Zeinabsadat Fattahi

Position

Pediatric Anesthesiology Fellowship

Latest degree

Subspecialist

Other areas of specialty/work

Anesthesiology

Street address

Anesthesiology Department, Faghihi Hospital, Zand Street

City

Shiraz

Province

Fars

Postal code

7193711351

Phone

+98 71 3647 4270

Email

parniafattahi@rocketmail.com

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Hamide Saeedizade

Position

Research Assistant

Latest degree

Bachelor

Other areas of specialty/work

Medical Informatics

Street address

Anesthesiology Department, Faghihi Hospital, Zand Street

City

Shiraz

Province

Fars

Postal code

7134844119

Phone

009836281460

Email

saeedi.hamide@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

It is against our policy

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available